Gossamer Bio, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
3115 MERRYFIELD ROW, SAN DIEGO, CA, 92121
Mailing Address
3115 MERRYFIELD ROW, SAN DIEGO, CA, 92121
Phone
(858) 684-1300
Fiscal Year End
1231
EIN
475461709
Financial Overview
FY2025
-$56.53M
Net Income
$295.01M
Total Liabilities
$62.77M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 10-K Annual financial report | March 17, 2026 | View on SEC |
| 8-K Current report of material events | March 17, 2026 | View on SEC |
Material Events
8-K
Strategy Change
March 17, 2026
High Impact
- Seralutinib showed potential benefits in specific patient groups, especially those with more severe disease (on three different therapies).
- Seralutinib demonstrated good results across several important secondary measures in the PROSERA trial.
8-K
Strategy Change
February 23, 2026
High Impact
- Seralutinib showed positive and statistically significant results in key secondary endpoints, including NT-proBNP reduction (25% vs. 5% for placebo, p<0.01) and a favorable trend in reducing clinical worsening events.
- Robust and statistically significant improvements in 6-minute walk distance (+45-50 meters, p<0.01) and other measures were observed in specific, pre-defined patient subgroups, such as those with more severe PAH (WHO Functional Class III/IV) or CTD-PAH.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.